Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 36M | 8M | 5M | 9M | 12M |
| Gross Profit | 32M | 5M | 4M | 8M | 12M |
| Operating Income | -12M | -66M | -66M | -21M | -31M |
| EBITDA | -11M | -66M | -62M | -22M | -30M |
| Net Income | -18M | -77M | -67M | -24M | -35M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$5.63
-3.43% today
1Y Change
-2.39%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Verrica Pharmaceuticals Inc. (VRCA) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $5.63 and down 2.4% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +370.2%, EPS growth of +88.6%, a dividend yield of 0.0%. What stands out right now is revenue +370.2%, EPS +88.6%, free cash flow +71.1% with operating margin -33.6% and ROIC -38.0%. Valuation is more restrained than many high-expectation growth names at price/sales 1.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VRCA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VRCA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VRCA Max Drawdown
-62.43%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VRCA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$12.0M
+32.9% YoY
FY Net Income
-$35.1M
-43.3% YoY
Free Cash Flow
-$28.5M
-50.2% YoY
Revenue Growth
+370.2%
EPS Growth
+88.6%
Gross Margin
90.8%
Net Margin
-50.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 36M | 8M | 5M | 9M | 12M |
| Gross Profit | 32M | 5M | 4M | 8M | 12M |
| Operating Income | -12M | -66M | -66M | -21M | -31M |
| EBITDA | -11M | -66M | -62M | -22M | -30M |
| Net Income | -18M | -77M | -67M | -24M | -35M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 30M | 46M | 70M | 34M | 16M |
| Total Assets | 47M | 54M | 82M | 45M | 80M |
| Total Liabilities | 22M | 64M | 62M | 5M | 48M |
| Shareholder Equity | 25M | -10M | 20M | 40M | 33M |
| Total Debt | 2M | 46M | 46M | 2M | 43M |
| Net Debt | -29M | -390K | -24M | -33M | 28M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
28M
-47.9% YoY
Capital Expenditures
883K
-192.4% YoY
Free Cash Flow
28M
-50.2% YoY
Key ratios
Gross Margin
90.8%
Operating Margin
-33.6%
Net Margin
-50.3%
ROE
252.3%
Debt / Equity
0.07x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.